UroGen Pharma Ltd share price logo

UroGen Pharma Ltd

NASDAQ: URGN

Small Cap

$28.30

-0.27

(-0.96%)

Live

as on

UroGen Pharma Ltd Stock Performance

as on May 20, 2026 at 2:16 am IST

  • Day's Low

    Day's High

    $27.34
    $28.68
    downward going graph

    3.39%

    Downside

    1.34%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.42
    $32.37
    downward going graph

    87.92%

    Downside

    14.38%

    Upside

    downward going graph

UroGen Pharma Ltd share price movements today

Previous Close
$28.58
Open
$27.90
Volume
282.9K
Day's Low - High
$27.34 - $28.68
52 Week Low - High
$3.42 - $32.37

UroGen Pharma Ltd Historical Returns

1 Month Return
+ 27.68 %
3 Month Return
+ 32.02 %
1 Year Return
+ 261.1 %
3 Year Return
+ 149.61 %
5 Year Return
+ 57.87 %

UroGen Pharma Ltd Stock Fundamentals & Key Indicators

Check UroGen Pharma Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.4B

EPS (TTM)

-0.8856

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-107.9M

Revenue (TTM)

140.5M

Profit Margin

-94.83%

Return On Equity TTM

-1481.26%

UroGen Pharma Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of UroGen Pharma Ltd with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
UroGen Pharma Ltd image
UroGen Pharma Ltd
BUY$1.4B57.87%NA-94.83%
Revolution Medicines Inc image
Revolution Medicines Inc
BUY$31.8B357.47%NA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.2B112.69%73.5512.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$115.0B104.13%26.8935.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.7B36.84%17.3929.65%

Stock Returns calculator for UroGen Pharma Ltd Stock including INR - Dollar returns

The UroGen Pharma Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

UroGen Pharma Ltd investment value today

Current value as on today

₹4,01,416

Returns

₹3,01,416

(+301.42%)

Returns from UroGen Pharma Ltd Stock

₹2,55,082 (+255.08%)

Dollar Impact

₹46,334 (+46.33%)

Analyst Recommendation on UroGen Pharma Ltd Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for UroGen Pharma Ltd. Average target price of $36.44

UroGen Pharma Ltd Share Price Target

Get share price movements and forecasts by analysts on UroGen Pharma Ltd.

What analysts predicted

22.34%UPSIDE

Target Price

$36.44

Current Price

$28.3

Analyzed by

11 Analysts

Target

$36.44

UroGen Pharma Ltd target price $36.44, a slight upside of 22.34% compared to current price of $28.3. According to 11 analysts rating.

Indian Investors' Interest in UroGen Pharma Ltd Stock

Search interest for UroGen Pharma Ltd Stock has increased by 146% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:146% versus previous 30 day period

UroGen Pharma Ltd Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
23
18
21
25
24
20
24
27
37
50
Gross Profit
21
17
19
22
22
17
20
24
34
46
Operating Income
-14
-25
-25
-17
-27
-36
-41
-27
-19
-20
EBITDA
-7
-23
-29
-14
-26
-38
-48
-25
-22
-19
Interest Expense
3
2
3
2
3
4
8
7
13
8
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-22
-32
-33
-23
-34
-43
-48
-34
-26
-28
Income Tax Expense
3
0
0
0
2
0
1
-1
0
-4
Net Income
-26
-32
-33
-23
-37
-43
-49
-33
-26
-23
Net Profit Margin
-110.57%
-171.91%
-152.89%
-93.93%
-152.71%
-216.47%
-206.24%
-121.34%
-69.68%
-46.26%

UroGen Pharma Ltd Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
17
8
1
0
11
48
64
82
90
109
Gross Profit
17
7
0
0
10
42
56
73
81
97
Operating Income
0
-19
-77
-109
-126
-92
-79
-65
-96
-124
EBITDA
1
-19
-76
-108
-124
-91
-76
-60
-95
-135
Interest Expense
-
-
-
0
3
17
8
14
12
33
Depreciation
-
0
0
1
2
1
1
1
1
2
Income Before Tax
-1
-19
-75
-105
-125
-109
-108
-98
-124
-153
Income Tax Expense
-
0
0
-4
3
1
1
3
2
0
Net Income
-1
-20
-75
-105
-128
-110
-109
-102
-126
-153
Net Profit Margin
-11.07%
-245.16%
-6707.18%
-584144.44%
-1088.94%
-230.67%
-170.58%
-123.61%
-140.35%
-139.81%

UroGen Pharma Ltd Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-32
-33
-23
-37
-43
-49
-33
-26
-23
Operating Cash Flow
-31
-23
-27
-13
-42
-39
-42
-38
-45
Investing Cash Flow
13
11
-106
60
-25
28
31
27
-20
Financing Cash Flow
54
100
39
0
0
0
8
31
65
Change in Cash
36
88
-94
47
-67
-11
-2
20
0

UroGen Pharma Ltd Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-20
-75
-105
-128
-110
-109
-102
-126
-153
Operating Cash Flow
-9
-37
-71
-105
-84
-87
-76
-96
-162
Investing Cash Flow
-36
35
-145
93
4
1
0
-20
61
Financing Cash Flow
61
66
165
16
72
97
116
194
39
Change in Cash
15
64
-51
3
-8
10
39
77
-60

Global Institutional Holdings in UroGen Pharma Ltd

Funds
Holdings
Rosalind Advisors, Inc.
1.17%
Paradigm Biocapital Advisors LP
9.18%
MENORA MIVTACHIM HOLDINGS LIMITED
2.37%
Soleus Capital Management, L.P.
4.72%
Orbimed Advisors, LLC
1.8%
See all

Insights on UroGen Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 5 quarters, 20.25M → 50.95M (in $), with an average increase of 20.3% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -49.94M → -23.57M (in $), with an average increase of 29.4% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, URGN stock has moved up by 27.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 463.5% return, outperforming this stock by 313.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 264.8% return, outperforming this stock by 3.7%

About UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
OrganisationUroGen Pharma Ltd
Headquarters400 Alexander Park Drive, Princeton, NJ, United States, 08540
IndustryBiotechnology
CEOMs. Elizabeth A. Barrett
E-voting on sharesClick here to vote

Key Management of UroGen Pharma Ltd

Name

Title

Ms. Elizabeth A. Barrett

President, CEO & Director

Mr. James Ottinger R.ph.

Executive Vice President of Regulatory Affairs & Quality

Mr. Michael J. Louie M.D., M.P.H., M.Sc.

Chief Development Officer

FAQs

What is UroGen Pharma Ltd share price today?

UroGen Pharma Ltd share price today is $28.3 as on . UroGen Pharma Ltd share today touched a day high of $28.68 and a low of $27.34.

What is the 52 week high and 52 week low for UroGen Pharma Ltd share?

UroGen Pharma Ltd share touched a 52 week high of $32.37 on and a 52 week low of $3.42 on . UroGen Pharma Ltd stock price today i.e. is trending at $28.3,which is 12.57% down from its 52 week high and 727.49% up from its 52 week low.

What is UroGen Pharma Ltd's market capitalisation today?

UroGen Pharma Ltd market capitalisation is $0.00T as on .

How to invest in UroGen Pharma Ltd Stock (URGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for UroGen Pharma Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in UroGen Pharma Ltd Shares that will get you 0.0530 shares as per UroGen Pharma Ltd share price of $28.3 per share as on May 19, 2026 at 8:46 pm IST.

What is the minimum amount required to buy UroGen Pharma Ltd Stock (URGN) from India?

Indian investors can start investing in UroGen Pharma Ltd (URGN) shares with as little as ₹96.5325 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹965.33 in UroGen Pharma Ltd stock (as per the Rupee-Dollar exchange rate as on ). Based on UroGen Pharma Ltd share’s latest price of $28.3 as on May 19, 2026 at 8:46 pm IST, you will get 0.3534 shares of UroGen Pharma Ltd. Learn more about fractional shares .

What are the returns that UroGen Pharma Ltd has given to Indian investors in the last 5 years?

UroGen Pharma Ltd stock has given 57.87% share price returns and 31.59% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?